- Hormonal Intrauterine Device
- Copper Intrauterine Device
- Combination Oral Contraceptives
- Progestin Only Oral Contraceptives
- Implants
- Vaginal Rings
- Others
US Total Birth Control Market size was valued at USD 6.4 billion in 2023 and is projected to reach USD 8.0 billion by 2028, at a CAGR of 3.8% from 2024 to 2030. The market's expansion can be attributed to increased sexual health awareness among adolescents and young people, improved access to Family Planning and Reproductive Health (FP/RH) services, and rising demand for birth-control pills in urban areas.
An increase in female workforce participation in the USA influences the US contraceptive market by driving demand for effective and convenient contraceptive methods. In terms of product categories, in 2023, the Combination oral contraceptives segment accounted for a 37.1% revenue share and is projected to grow at 3.4% CAGR over 2023 - 2029. Combination oral contraceptives, which contain both estrogen and progestin hormones, are approximately 99% effective with perfect use. Combination oral contraceptives are taken daily. In 2023, the Progestin Only Oral Contraceptives segment accounted for 18.4% of revenue and they are also taken daily, but they have a slightly less better at preventing pregnancy compared to combination pills. PBI anticipate that, Progestin is projected to grow at a faster growth rate in 2024 owing to the FDA approval of Opill, HRA Pharma (Perrigo) for OTC purpose which will impact the sales of other contraception methods.
Us Total Birth Control Market Key Developments:
- In August 2022, The long-acting intrauterine system Mirena™ was approved in the United States for an extended duration of use in contraception of up to 8 years. The corresponding approval procedure in Europe was positively concluded in October, and the first national approvals in the EU were granted in the fourth quarter of 2022.
- In 13th July 2023, the US FDA Approved the first ever over-the-counter birth pill in the United States. In addition to that, there will be no age restrictions on the sales of the pill. HRA Pharma, a unit of Perrigo, manufactures the Opill. The company plans to launch Opill in the first half of 2024. The company would like to place the brand in drugstores, convenience stores, grocery stores, and online retailers, among others. The company has launched the website Opill hcp to bring awareness of the product and continuous education.
US Total Birth Control Market Dynamics
In the United States, 45% of all pregnancies are unplanned. Increasing contraceptive availability is a proven method for reducing unwanted pregnancies and ensuring appropriate birth spacing. In the United States, an estimated 37.9 million women need contraceptive care. Women who want to delay or avoid pregnancy should be able to choose from a variety of contraceptive techniques, preferably on the same day and on-site. These contraceptive services must be offered in a client-centered way that respects, empathizes, and understands each person as a unique individual, giving accurate, easy-to-understand information based on the client's needs and goals, and reflecting the client's choices and beliefs. Male condoms are popular among young people due to their ease of use, low cost, and added benefit of protecting against STDs. Furthermore, the wide variety of sizes, flavors, textures, and thicknesses available enhances the sexual experience of users.
According to the Centers for Disease Control and Prevention (CDC), 14 % of women aged 15 to 49 are using contraceptive tablets by 2020. As a result, contraceptive pill use is widespread in the United States and is projected to continue in the coming years. Increasing interest in contraceptive pills because of the availability of cost-effective medications with similar bioavailability and bioequivalence to branded drugs, rising patient demand for generic drugs, and growing awareness about unwanted pregnancies, generic oral contraceptive tablets are becoming more popular. The oral contraceptive pill is a hormonal contraception therapy. Side effects are prevalent and differ from person to person. Birth control tablets alter a person's hormone levels, which can result in a variety of negative side effects. These side effects normally go away after 2–3 months, but they can remain which would impact the growth of the Total Birth Control Market.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Us Total Birth Control Market Segmentation
By Method
By End Users
- Hospitals
- Gynaecology Clinics
- Community Health Care Centers
- Homecare and Others
Frequently Asked Questions
The US Total Birth Control Market size was valued at USD 6.4 billion in 2023
Allergan, Mylan N.V., Bayer AG, Sandoz, The Cooper Companies Inc., Pfizer, Inc., Merck, DKT International, Afaxys, Inc., Syneos Health,Agile Therapeutics
The base year of the market study is 2023 and the forecast years is 2024-2030
| 1. Executive Summary |
| 2. US Total Birth Control Market Introduction |
| 2.1. US Total Birth Control Market Taxonomy |
| 2.2. US Total Birth Control Market Definitions |
| 2.2.1. By Method |
| 2.2.2. By End Users |
| 3. US Total Birth Control Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. US Total Birth Control Market Dynamic Factors - Impact Analysis |
| 3.6. US Total Birth Control Market Competition Landscape |
| 4. US Total Birth Control Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. US Total Birth Control Market, By Method, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Hormonal Intrauterine Device |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Copper Intrauterine Device |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Combination Oral Contraceptives |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Progestin Only Oral Contraceptives |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Implants |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Vaginal Rings |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. US Total Birth Control Market Forecast, By End Users, 2019 - 2023 and Forecast, 2020 2026 (Revenue, USD Mn) |
| 6.1. Hospitals |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Gynaecology Clinics |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Community Health Care Centers |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Homecare |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Strategic Dashboard of Top Market Players |
| 7.2. Company Profiles (Introduction, Financial Analysis, Method & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 7.2.1. Allergan |
| 7.2.2. Mylan N.V. |
| 7.2.3. Bayer AG |
| 7.2.4. Sandoz |
| 7.2.5. The Cooper Companies Inc. |
| 7.2.6. Pfizer, Inc. |
| 7.2.7. Merck |
| 7.2.8. DKT International |
| 7.2.9. Afaxys, Inc. |
| 7.2.10. Syneos Health |
| 7.2.11. Agile Therapeutics |
| 8. Research Methodology |
| 9. Key Assumptions and Acronyms |
- Allergan
- Mylan N.V.
- Bayer AG
- Sandoz
- The Cooper Companies Inc.
- Pfizer, Inc.
- Merck
- DKT International
- Afaxys, Inc.
- Syneos Health
- Agile Therapeutics